{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"21.2","upperLimit":"43.4","value":"31.5"},{"groupId":"OG001","lowerLimit":"24.9","upperLimit":"48.0","value":"35.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"53"}],"units":"Participants"}],"description":"\"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive a placebo IV over 30-90 minutes on day 1, gemcitabine hydrochloride IV over 90 minutes on days 1 and 8, and docetaxel IV over 60 minutes on day 8. Patients also receive filgrastim subcutaneously (SC) on days 9-15 or pegfilgrastim SC on day 9 or 10.\n\nDocetaxel: Given IV\n\nFilgrastim: Given SC\n\nGemcitabine Hydrochloride: Given IV\n\nPegfilgrastim: Given SC\n\nPlacebo: Given IV","id":"OG000","title":"Arm I Gem+Doce+Placebo"},{"description":"Patients receive bevacizumab IV over 30-90 minutes on day 1, gemcitabine hydrochloride IV over 90 minutes on days 1 and 8, and docetaxel IV over 60 minutes on day 8. Patients also receive filgrastim SC on days 9-15 or pegfilgrastim SC on day 9 or 10.\n\nBevacizumab: Given IV\n\nDocetaxel: Given IV\n\nFilgrastim: Given SC\n\nGemcitabine Hydrochloride: Given IV\n\nPegfilgrastim: Given SC","id":"OG001","title":"Arm II Gem+Doce+Bev"}],"paramType":"NUMBER","populationDescription":"All randomized","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Objective Response Rate as Measured by RECIST 1.1 Criteria","type":"SECONDARY","unitOfMeasure":"percentage of participants"}